 |
|
|
| |
A COMBINATION OF VIRAL AND PARTICIPANT FACTORS INFLUENCE VIROLOGIC OUTCOME TO LONG-ACTING CABOTEGRAVIR + RILPIVIRINE: MULTIVARIABLE AND BASELINE FACTOR ANALYSES ACROSS ATLAS, FLAIR AND ATLAS-2M PHASE 3 STUDIES
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
David A. Margolis1, Jonathan M. Schapiro2, Carlo Federico Perno3, Daniel R. Kuritzkes4, Romina Quercia5, Parul Patel1, Joseph W. Polli1, Amy Cutrell1, David Dorey6, Yongwei Wang7, Sterling Wu8, Veerle van Eygen9, Herta Crauwels9, Susan L. Ford10, Mark Baker11, Christine Talarico1, Marty St. Clair1, Jerry Jeffrey1, C. Thomas White1, Simon Vanveggel9, Rodica Van Solingen-Ristea9, Kati Vandermeulen9, William R. Spreen1, Jan van Lunzen12
1ViiV Healthcare, Research Triangle Park, NC, United States; 2National Hemophilia Center, Sheba Medical Center, Ramat Gan, Israel; 3IRCCS Bambino Gesł Pediatric Hospital, Rome, Italy; 4Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; 5ViiV Healthcare, Brentford, United Kingdom; 6GlaxoSmithKline, Mississauga, Canada; 7ViiV Healthcare, Collegeville, PA, United States; 8GlaxoSmithKline, Collegeville, PA, United States; 9Janssen Research
and Development, Beerse, Belgium; 10GlaxoSmithKline, Research Triangle Park, NC, United States; 11ViiV Healthcare, Nyon, Switzerland; 12ViiV Healthcare, Munich, Germany
|
| |
|
|
|
|
|
